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Aim of the study: The objective of 
the study was to present the prelimi-
nary results of proton radiotherapy as 
a method for treating 15 patients with 
choroidal melanoma.
Material and methods: The proton 
radiotherapy was administered using 
beams providing energy levels of 60 
MeV, which ensures a clinical range 
of 28.4 mm. In addition, the beam 
has a very narrow penumbra of 1.3 
mm and a sharp distal dose fall-off. 
All patients received the dose of 60 
CGE (cobalt gray equivalent) given to 
the PTV (planning target volume). This 
dose was administered in 4 fractions 
over 4 successive days of treatment.
Results: The tumour had regressed in 
8 patients (53.3%) and remained stable 
in 3 patients (20%). The large tumours 
in another 3 patients (20%) were re-
moved during vitrectomy (endoresec-
tion), which increased the number of 
patients with tumour regression up to 
11 (73.3%). In the case of 1 patient, 
despite intraocular tumour regression 
occurring the choroidal melanoma 
had spread multifocally into the orbit, 
which necessitated orbit exenteration. 
The results ensured that the eyeballs 
of 14 patients (93.3%) could be saved.
The follow-up period for the 15 pa-
tients ranged between 8 and 26 
months (average: 17.4 months, medi-
an: 19 months). In this period some 
side effects were noted: an increase 
in intraocular pressure, retinal detach-
ment, cataract, maculopathy, neurop-
athy and vitreous haemorrhaging.
Conclusions: The preliminary results 
confirm that proton radiotherapy is an 
effective method for treating patients 
with choroidal melanoma. This meth-
od ensures an eyeball preservation 
rate of 93%, with the vision function 
of 80% of the patients being saved.
Key words: ocular melanoma, choroi-
dal melanoma, proton radiotherapy.
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Introduction
Ocular melanoma is a rare malignant neoplasm with the incidence rate 
estimated at 6–8 cases per one million [1, 2]. This translates into 3.7% of all 
cases of melanoma and makes it the second most frequent location for this 
neoplasm (after skin melanomas [1, 3]). On the other hand, choroidal mel-
anoma is one of the most common primary intraocular malignant tumours 
affecting the eyeball and in most cases (82.5%) develops in the uvea.
The following are predisposing factors for choroidal melanoma: congeni-
tal ocular or oculodermal melanocytosis (nevus of Ota) and uveal nevus [4]. 
Furthermore, more than half of all patients have somatic mutations of the 
following genes: GNAQ, PTEN, GNA11 [5–10]. This carcinoma is most com-
monly diagnosed in persons aged 50–80 with fair skin colour, light eye col-
our and with reduced tolerance to sunlight.
Symptoms of choroidal melanoma depend on the location and dimen-
sions of the tumour. They include the following: various visual disturbances 
(impaired vision with varying degrees of severity up to visual loss in the 
affected eye), photopsia, irritation and pain. It is important to note that 30% 
of tumours are asymptomatic and are only detected by accident during eye 
examinations [11, 12].
The basic treatment methods applied to patients with ocular choroidal 
melanoma are surgery and radiotherapy. The choice of treatment for pa-
tients with ocular choroidal melanoma depends on the location and size of 
the tumour, its local advancement, the effectiveness of a given method and 
its impact on maintaining the patient’s visual function.
Possible surgical treatment includes procedures aimed at preserving the 
eyeball (endoresection or exoresection of the tumour) as well as more ex-
tensive operations such as enucleation of the eyeball [3].
Radiotherapy treatment is aimed at preserving the eyeball. It can take the 
form of either brachytherapy or teletherapy.
In the case of brachytherapy applicators are used (in the form of plaques) 
with a radioactive isotope (iodine-125, ruthenium-106, palladium-103) [13, 14]. 
This method has been practised since the 1930s and its 5-year survival rate 
of around 80% is comparable with the results observed for enucleation 
[15, 16]. Thanks to these factors and the possibility of preserving the eyeball, 
brachytherapy has become the standard procedure for patients with choroidal 
melanoma. However, the method has certain limitations due to post-radiation 
reaction and the risk of complications occurring in the healthy tissue surround-
ing tumours. This is the case with tumours located in the region of the macula 
and the optic disc, those that infiltrate the sclera and which are large in size.
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The second radiotherapy method for treating patients 
with choroidal melanoma is teleradiotherapy, which makes 
use of stereotactic techniques (e.g. a gamma knife) togeth-
er with intensity-modulated radiation therapy (IMRT) or 
a proton beam [3, 17, 18].
Local treatment makes it possible to preserve the eye-
ball and its functioning. However, it does have some ef-
fect on the survival rate [19, 20]. A particular role is played 
here by proton radiotherapy, which has been used to treat 
choroidal melanoma since the 1970s as an alternative 
procedure to enucleation (in the case of large tumours) or 
brachytherapy (in the case of tumours located close to the 
macula or the optic disc) [19, 21–24].
According to data from the PTCOG (Particle Therapy 
Co-Operative Group), patients with ocular melanoma make 
up 20% of all patients treated with proton radiotherapy [25].
In February 2011 in Kraków patients with choroidal mel-
anoma began to be treated with proton radiotherapy.
Aim of the study
The objective of the study was to present the prelimi-
nary results of proton radiotherapy as a method for treat-
ing patients with choroidal melanoma.
Material and methods
Between February 2011 and March 2012 a total of 15 
patients with choroidal melanoma underwent proton ra-
diotherapy.
This group consisted of 7 women (46.7%) and 8 men 
(53.3%). The patients ranged in age between 38 and 74 
with an average age of 56.1 (median 57 years).
The location and size of the tumour in the eyeball were 
determined in eye examinations conducted at the Depart-
ment of Ophthalmology and Ocular Oncology Clinic, Jagi-
ellonian University.
Patients
Presented in Table 1 are the characteristics of choroidal 
melanoma in the 15 patients.
In 10 of the 15 patients (66.7%) the tumour was locat-
ed in the right eyeball. The tumour was predominantly 
located in the temporal quadrants of the choroid (53.3% 
of patients). Advanced T3 stage cancer was observed in 
40% of the patients. The average distance of the margin 
of the tumour from the optic disc was 3.5 mm, and from 
the macula it was 2.21 mm. The average dimensions of the 
transverse (crosswise) and longitudinal (lengthwise) base 
of the tumour were 11.24 mm and 11.44 mm, respective-
ly. The tumour thickness varied between 1.4 mm and 10.6 
mm and was on average 5.05 mm.
Proton radiotherapy procedure
The proton radiotherapy was administered using 
beams emitted from an AIC-144 isochronic cyclotron at the 
Institute of Nuclear Physics PAN in Kraków. These beams 
provide energy levels of 60 MeV, which ensures a clinical 
range of 28.4 mm. In addition, the beam has a very narrow 
penumbra of 1.3 mm and a sharp distal dose fall-off.
Prior to administering proton radiotherapy tantalum 
markers were sown to the sclera of the eyeball (an exam-
ple is presented in Fig. 1) and the distance was measured 
between the markers and the corneal limbus as well as 
between the markers and the edge of the tumour. The 
position of the markers was verified using imaging tests 
(USG, CT, MRI). Figure 2 shows an example of marker posi-
tion verification using magnetic resonance imaging (MRI).
Table 1. Characteristics of 15 patients with choroidal melanoma
Clinical features No. of patients %
Treated eye
   right
   left
10
5
55.7
33.3
Tumour localization – part of fundus:
   temporal
   temporal – upper
   temporal – lower
   nasal – upper
   nasal – lower
   lower
   optic disc
3
3
2
3
1
2
1
20.0
20.0
13.3
20.0
6.7
13.3
6.7
Tumour stage according to TNM system
   T1
   T2
   T3
4
5
6
26.7
33.3
40.0
Values of distance and diameters Range Mean Median Standard deviation
Tumour distance to:
   optic disc [mm]
   macula [mm]
0–7.50
0–5.25
3.50
2.21
3.30
2.50
2.13
1.97
Tumour diameters [mm]
   transverse basal 
   longitudinal basal
   tumour thickness
8.10–17.40 
7.80–16.20
1.40–10.30
11.24
11.44
5.05
10.50
10.60
3.50
2.59
2.75
2.98
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Based on the measurements and the clinical data and 
using a computerised treatment planning system, we cre-
ated a virtual model of the eyeball with a reconstructed 
tumour. Radiotherapy planning was based on the Eclipse 
Ocular Proton Planning system developed by the company 
Varian Medical Systems.
The plan was to cover 90% of the planning target vol-
ume (PTV) content (tumour with margin of 2.5 mm) with 
isodose.
Figure 3 presents the dose distribution in PTV and 
dose-volume histograms in PTV and critical organs.
To ensure that the beam had the appropriate range and 
achieved a homogeneous dosage in PTV, we used individ-
ually selected beam modifiers (range discriminator, power 
modulator and collimator).
A dose of 60 CGE was administered in 4 fractions over 
4 successive days of treatment.
Methods
At the end of the treatment the patients continued to 
be monitored as outpatients at the Department of Oph-
thalmology and Ocular Oncology Clinic, Jagiellonian Uni-
versity. During the study the clinical effects of proton ra-
diotherapy were measured in terms of effectiveness and 
toxicity.
The effectiveness of proton radiotherapy was assessed 
as the degree of tumour regression while taking into ac-
count changes in the dimensions of the tumour. During 
the follow-up the side effects of the treatment and the pa-
tient’s vision function were also monitored.
Student’s t-test was used to compare the sizes of tu-
mours and change of vision function prior to and after 
treatment, adopting α = 0.05 as the level of statistical sig-
nificance.
Results
The effects of the treatment, assessed as the frequency 
of regression and change in tumour size and change of vi-
sion function, are presented in Table 2.
Measurements of the tumours (their transverse and 
longitudinal base as well as their thickness) showed a sig-
nificant reduction in size following proton radiotherapy.
Figure 4 presents an example of a USG image taken be-
fore and after proton radiotherapy.
Following proton radiotherapy the tumour had re-
gressed in 8 patients (53.3%) and remained stable in 
3 patients (20%). The large tumours in another 3 patients 
(20%) were removed during vitrectomy (endoresection), 
which increased the number of patients with tumour re-
gression up to 11 (73.3%). In the case of 1 patient, despite 
intraocular tumour regression occurring the choroidal mel-
anoma had spread multifocally into the orbit, which neces-
sitated orbit exenteration.
The results ensured that the eyeballs of 14 patients 
(93.3%) could be saved.
After proton radiotherapy distant best corrected visual 
acuity (BCVA) increased in 1 case, was stable in 5 and de-
creased in 9 patients.
The follow-up period for the 15 patients ranged be-
tween 8 and 26 months (average: 17.4 months, median 
tantalum  
markers
tantalum 
markers
A
B
Fig. 1. The example of tantalum markers on the sclera of the eyeball Fig. 2. The example of verification (A) and measurement of distance 
(B) of markers using MRI
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A B
C
Fig. 3. The dose distribution in PTV: A) isodoses distribution, B) Beam’s eye view, and dose-volume histograms of tumour and critical organs (C)
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Table 2. Results after proton radiotherapy in a group of 15 patients with choroidal melanoma
Results No. of patients %
Clinical results
   regression
   stabilization
   progression (metastases)
11*
3
1
73.3
20.0
6.7
Vision function
   improvement
   stabilization
   deterioration
1
5
9
6.7
33.3
60.0
Tumour diameters (mean values) Before treatment After treatment p (Student’s t-test) 95% confidence interval
transverse basal [mm] 11.24 9.30 0.0003 2.06–2.30
longitudinal basal [mm] 11.44 8.83 0.0246 0.36–4.24
tumour thickness [mm] 5.05 2.67 0.0061 0.49–2.28
*In 3 of these patients tumour endoresection was performed
tumour
tumour regression
D
B
C
A
Fig. 4. The examples of USG images performed before (A, B) and after (C, D) proton radiotherapy in one of patients. There are corresponding 
pictures A with C and B with D
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Table 3. Side effects of proton radiotherapy observed in group of 15 pa-
tients with choroidal melanoma
Complication No. of patients %
glaucoma 9 60.0
worsening of visual acuity 1 6.7
retinopathy 1 6.7
cataract 2 13.3
neuropathy 1 6.7
maculopathy 1 6.7
vitreous haemorrhaging 1 6.7
value: 19 months). In this period some side effects were 
noted in the observation period, which are presented in 
Table 3.
An increase in intraocular pressure was observed in 
9 of the patients (60%). This increase amounted on aver-
age to 2.8 mm Hg (range 1–6 mm Hg) compared with the 
pre-treatment levels. On the other hand, in certain individ-
ual cases other complications developed, such as retinal 
detachment, cataract, maculopathy, neuropathy and vitre-
ous haemorrhaging.
Discussion
Proton radiotherapy treatment for patients with uveal 
melanoma is a conservative local method that has been 
employed since the 1970s and is regarded as one of the 
basic approaches to treating such patients [21].
Proton beams are used in radiotherapy due to their 
physical properties (limited range, sharp lateral penum-
bra, no increased dose effect on beam entry and practi-
cally no dose on beam exit), thanks to which it is possible 
to achieve a homogeneous distribution of a large dose in 
a limited volume (tumour with margin) while simultane-
ously ensuring excellent protection for healthy tissue and 
the vital organs by limiting the dose and irradiated volume 
[26, 27].
This method offers very good results in terms of local 
control (89–99%), with the eyeball preserved in more than 
90% of cases and vision function maintained in more than 
50% [19, 23, 28–38].
In the case of our own material, tumour regression was 
achieved in 73% of patients, the eyeball was saved in 93% 
and vision function in 90% of cases. It is important to note 
that these are only preliminary results for a group of 15 
patients and were obtained over a relatively short obser-
vation period (median 19 months).
Proton radiotherapy represents an alternative to 
brachytherapy as a means of treating tumours located 
close to the macula or optic disc. Better results in terms of 
local control were observed following proton radiotherapy 
than was the case with brachytherapy, with no significant 
differences in survival rates [13, 39, 40]. The positive im-
pact of proton radiotherapy on treatment can be seen in 
the reduced frequency of relapses or complications (pri-
marily retinopathy and cataracts) following such treat-
ment [41]. This translates into fewer cases requiring enu-
cleation. The risk of enucleation due to complications is 
reduced by 47% after proton radiotherapy compared with 
brachytherapy [13].
In turn, Wilson et al. observed greater vision impair-
ment with proton radiotherapy than was the case with 
brachytherapy [14].
A very important factor to consider is proton radiothera-
py’s impact on the patient’s vision. According to data from 
the literature, the chances of preserving the patient’s sight 
depends on the location of the tumour. The vision function 
of 33–47% of the patients had deteriorated 1–2 years after 
proton radiotherapy when the tumour was located in the 
region of the macula or optic disc and in 17–28% of cases 
when the tumour was in a different location [24, 33].
In our material choroidal melanoma were located close 
to the macula and/or optic disc in 9 of 15 cases and it ex-
plains the visual acuity of 60% of patients during an aver-
age 17.4-month observation period.
The clinical effectiveness of proton radiotherapy (local 
control) can be improved by ensuring possible endoresec-
tion of the remaining part of the tumour [42]. This helps 
improve the outcome of treatment while at the same time 
preserving the eyeball.
Through local control and limiting the frequency of 
complications the eyeball can be saved, which is a very im-
portant argument in favour of proton radiotherapy.
Egger et al. analysed the material from 15 years ago 
(1984–1999) covering 2648 eyes in 2645 patients. They 
demonstrated that the most common reasons for enu-
cleation were the following: loss of function, glaucoma, 
inflammation and cancer relapse. According to these re-
searchers, the size of the tumour has a significant influ-
ence on whether the eyeball can be preserved. The 5- and 
10-year eyeball preservation rates were 100% and 96.1% 
(for small tumours) and 99.7% and 64.8% (for large tu-
mours), respectively [19].
Aziz et al. noted the following complications following 
proton radiotherapy: retinopathy (39%), cataracts (20%), 
inflammation of the uvea (17%), neuropathy (16%) and 
maculopathy (4%). Despite this fact, when the results in 
terms of local control are considered, the authors believe 
that proton radiotherapy is an effective method for treat-
ing patients with choroidal melanoma [15].
The most common side effect of proton radiotherapy 
revealed in our own material was increased intraocular 
pressure (60% of patients), while other complications only 
occurred in individual cases. As mentioned earlier, it is im-
portant to bear in mind that the observation period for the 
group in the present study was short and the group itself 
comprised 15 patients.
One advantage of proton radiotherapy is that it ensures 
a homogeneous dose distribution in a limited volume. The 
application of advanced photon radiotherapy techniques 
(stereotactic, gamma knife, IMRT) makes it possible to 
achieve a comparable high dose distribution [17, 18]. The 
differences lie in the excellent protection of healthy tissue 
and the critical organs, and it is precisely here where pro-
ton radiotherapy has the edge.
In summary, our preliminary results concerning 
a small group of 15 patients with a median observation 
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period of 19 months confirm that proton radiotherapy is 
an effective method for treating patients with choroidal 
melanoma.
This method ensures an eyeball preservation rate of 93%, 
with the vision function of 80% of the patients being saved.
Nevertheless, our preliminary results and those pub-
lished in the literature confirm that proton radiotherapy 
is an effective and safe method for treating patients with 
choroidal melanoma.
The authors declare no conflict of interest.
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